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Using a double-blind, randomized and counterbalanced, cross-over design, we assessed naproxen's effects on
gastrointestinal (GI) distress and performance in eleven volunteers (6 male, 5 female). Participants completed 4
trials: 1) placebo and ambient); 2) placebo and heat; 3) naproxen and ambient; and 4) naproxen and heat. In-
dependent variables were one placebo or 220mg naproxen pill every 8 h (h) for 24 h and ambient (22.7 1.8C)
or thermal environment (35.7 1.3C). Participants cycled 80min at a steady heart rate then 10min for
maximum distance. Perceived exertion was measured throughout cycling. Gastrointestinal distress was assessed
pre-, during, post-, 3 h post-, and 24 h post-cycling using a GI index for upper, lower, and systemic symptoms. No
statistically significant differences occurred between conditions at any time for GI symptoms or perceived exer-
tion, distance, or heart rate during maximum effort. A 24 h naproxen dose did not significantly affect performance
or cause more frequent or serious GI distress when participants were euhydrated and cycling at moderate intensity
in a thermal environment.Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) decrease pain and
inflammation by inhibiting cyclooxygenase (COX). COX-1 is constitu-
ently expressed to maintain renal blood flow, platelet aggregation, and
gastric mucus secretions, while COX-2 is upregulated in response to
trauma/illness and produces pain, inflammation, and fever.1 Due to
differing chemical structures and ingredients, each NSAID varies in its
mechanism of action, dosage, and effectiveness. For example, aspirin has
greater COX-1 selectivity, making aspirin effective at reducing cardio-
vascular events (e.g., blood clots) but less effective at reducing moderate
to severe pain and inflammation.2,3 Comparatively, naproxen is more
COX-2 selective, meaning it is less effective at reducing cardiovascular
events but more effective on pain and inflammation.2
Physically active individuals use prescription and over-the-counter
NSAIDs prophylactically or as treatment following injury in order to
“continue playing”.4–8 NSAIDs are perceived to improve performance bypartment of Health, Sport, and E
erson).
2020
uction and hosting by Elsevier B.Vmitigating pain and fatigue,6 which would subsequently improve time to
exhaustion, number of maximum repetitions, or other objective physio-
logical (e.g., blood lactate, creatine kinase) and subjective (e.g., rate of
perceived exertion [RPE], pain score) performance variables. Existing
literature regarding NSAID use in sport is conflicting and primarily fo-
cuses on aspirin, males, and short, intense exercise bouts in ambient
environments.9–12 A low aspirin dose (10mg kg1 of bodyweight) 1 h (h)
before maximum lower extremity resistance exercises increased RPE and
perceived leg pain compared to placebo.11 A 20mg kg1 aspirin dose 1 h
before exercise did not significantly affect power output, RPE, heart rate
(HR), or alleviate muscle pain during a ramped maximum exertion
cycling protocol.10 A 975mg aspirin dose 1 h before maximal graded
treadmill runs significantly increased RPE,9 and a 1200mg ibuprofen
dose 1 h before treadmill running did not improve time to exhaustion or
RPE and resulted in no significant change to HR.12 Acute NSAID use,
particularly aspirin and ibuprofen, appears to have little effect on per-
formance and, in some instances, may degrade it.xercise Sciences, 1301 Sunnyside Avenue, Robinson, Room 161, Lawrence, KS,
. on behalf of KeAi. This is an open access article under the CC BY-NC-ND license
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known to cause perforations, hemorrhaging, and increased epithelial
permeability along the gastrointestinal (GI) tract.13–15 As a result of
direct GI damage, and exacerbated by stress, fatigue, diet, and a number
of other factors (e.g., health status, medication use), individuals may
experience subjective GI distress symptoms such as nausea, cramping,
diarrhea, etc.16–18 Furthermore, NSAIDs increase cardiovascular strain
by inducing vasoconstriction and increasing peripheral and renal blood
vessel pressure.19 Presumably, NSAID driven effects on the GI and car-
diovascular systems could decrease performance. Among male
ultra-distance runners, a 400mg ibuprofen dose 15min prior to a 42 km
trail race (and an additional dose 5 h into the race) resulted in no sig-
nificant differences in cardiovascular measures or overall perceived pain
scores post-race compared to control.20 Two 325mg aspirin doses or
2–200mg ibuprofen doses 24 h prior to a 1 h treadmill run in a ther-
moneutral environment elicited no significant differences in HR, RPE, or
GI symptoms.15
Due to differing mechanisms of action and COX selectivity, it is
important to study non-aspirin NSAIDs, such as naproxen, on perfor-
mance and GI distress. Further, there is a lack of literature on physio-
logical and perceptual responses in thermal environments with longer
exercise sessions and including females. This research was part of a larger
study examining naproxen's effects on thermoregulation, inflammation,
GI damage, and hydration-electrolyte balance, which can all impact
performance and perceived GI distress symptoms. The primary aim of
this study was to determine the effects of an acute, over-the-counter
naproxen dose on GI distress symptoms and performance during
moderate-intense cycling in a thermal environment. We hypothesized
naproxen would induce significantly more GI distress and decrease per-
formance compared to placebo controls and that these effects would be
exacerbated with heat stress.
Materials and methods
We utilized a double-blind, randomized and counter-balanced, cross-
over design. Participants completed 4 conditions: 1) placebo and ambient
(Control); 2) placebo and heat (Heat); 3) naproxen and ambient (Npx);
and 4) naproxen and heat (NpxHeat). Aminimum of 7 days rest separated
each trial to ensure there were no residual naproxen or exercise effects
prior to the next trial. All trials took place in an environmental chamber
(thermal¼ 35.7 1.3C, 53.2 3.2% relative humidity) or laboratory
(ambient¼ 22.7 1.8C, 52.4 5.5% relative humidity). A 24 h dose (3
capsules) of placebo (cellulose) or naproxen sodium was given to par-
ticipants before data collection. The 24 h dose was similar to previous
research examining GI effects.15,21,22 A local pharmacy compounded the
capsules to look the same to blind participants and primary investigators
to whether a trial was naproxen or placebo. Each naproxen pill contained
220mg of naproxen sodium, the dose found in over-the-counter Aleve®.
A research assistant randomized participants into a trial order and pre-
pared capsules in coded, sealed envelopes. Participants consumed 1
capsule at 16 h, 8 h, and 0 h before data collection. All participants were
given specific take-home instructions to follow 24 h before data collec-
tion. Directions for taking each capsule (i.e., timing and taking with at
least 8 oz of fluid and not with food) were based on manufacturer di-
rections for over-the-counter Aleve® and were intended to maximize
potential naproxen induced GI effects. Dependent variables included HR,
RPE, distance covered during a 10min time trial, perceived GI distress
symptoms, and GI bleeding. Measures were assessed pre-, during, post-
and 3 h post-cycling.
Participants
Seventeen participants (12 males, 5 females) were recruited from the
university and local community. Attrition occurred due to the study's
intensity (n¼ 2), time commitment (n¼ 3), and a non-study related
injury (n¼ 1). The final sample size was 11 participants (6 male, 520female; age¼ 27.8 6.5 years, weight¼ 79.1 17.9 kg,
height¼ 177 9.5 cm, and V_O2max¼ 41.4 5.7ml kg1⋅min1). Partic-
ipants signed an Institutional Review Board approved informed consent
form. To be included in the study, participants had to be between 18-35
years old and not currently taking prescription or non-prescription anti-
inflammatory or pain medication. Potential participants completed a
health and injury history questionnaire and were excluded if they had
cardiovascular, respiratory, metabolic, GI, swallowing, or fluid-
electrolyte balance disorders or musculoskeletal disorders preventing
exercise. Females were asked additional questions about menstrual cycle
to identify menstrual regularity and oral contraception use. Potential
participants then completed a graded cycling V_O2max test and were
included in the study if they met the criteria for being recreationally
active (male V_O2max between 35-40mL kg1⋅min1; female between 32-
40mL kg1⋅min1).23 Once included in the study, participants were
familiarized with the online diet and activity log and instructed not to
take any analgesic or anti-inflammatory medications or use any treat-
ments (e.g., ice or other pain/inflammation relieving techniques) during
the study.
Procedures
Cycle exercise protocol
Participants completed a 98min cycling protocol on a stationary bike
(Monark Ergomedic 828E, Monark Exercise AB, Vansbro, Sweden). The
bike was calibrated according to the manufacturer's directions prior to
data collection. During the information session, the V_O2max test was
conducted on the same stationary cycle to familiarize individuals to the
bike, to working at maximum effort, and to establish the seat and han-
dlebar arrangement to ensure the same set-up was done for each exper-
imental trial.
Participants began with a 3min warm-up followed by cycling
80min at a steady HR equivalent to 70% V_O2max.24 To assess perfor-
mance, the final 10min mimicked a “time trial” where participants
cycled at maximum effort. Participants received verbal encouragement
from researchers throughout the entire 10min. For additional motiva-
tion, the top 5 mileages completed during the 10min were posted on a
board in the laboratory and researchers encouraged participants to try to
“get on the board” or beat a certain mileage. The cycling protocol
concluded with a 5min cool down.
Rate of perceived exertion (RPE)
The Borg Scale measured participants’ RPE pre-, every 15min during
the 80min steady state, and at 90min.
Cardiovascular
To ensure participants remained at safe limits and help maintain
target HR during 80min steady state cycling, HR was continuously
monitored and recorded every 5min using Polar HR monitors (Polar
Electro Inc., Lake Success, NY). To determine effects on performance,
maximum HR was measured at the end of the 10min maximum effort.
Core temperature (Tc)
Due to the larger study and to ensure participants remained at safe
levels during exercise, Tc wasmonitored using rectal thermometry (Doric
450 Series digital thermometer, VAS Engineering, Inc., San Diego, CA).
Participants were not allowed to exceed 40C.
Gastrointestinal distress
Fecal occult blood (FOB) was measured using guaiac-based take-
home kits (Fisher HealthCare™ Sure-Vue™ Fecal Occult Blood Slide
Tests System, Thermo Fisher Scientific Inc., Waltham,MA). By measuring
heme-, guaiac-based FOB has high specificity for detecting blood from
any portion of the GI tract (i.e., stomach, small intestine, and/or colon).
Participants were provided written and verbal instructions (based on the
manufacturer's directions) for collecting fecal samples. For each
Table 1
Performance measures during cycling for experimental conditions (M SD).
Control Heat Npx NpxHeat
Distance (miles) 3.2 0.8 2.9 0.8 3.3 0.8 2.8 0.8
Max HR (bpm) 175.7 14.2 177.8 18.2 176.2 15.0 179.0 18.0
RPE
Pre 8 2 9 3 9 3 8 2
80min 13 2 12 2 13 3 12 2
Post 19 2 18 2 19 2 19 2
No significant differences between conditions.
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initiating naproxen/placebo and the first stool sample following the ex-
ercise protocol. Kits were returned to the investigators on the day of the
second sample and immediately analysed following the manufacturer
directions.
The GI symptom index was developed based on a previously designed
questionnaire25,26 and is divided into 3 sections: 1) upper abdominal
problems (heart burn, reflux, belching, bloating, stomach pain/cramp-
ing, nausea, vomiting); 2) lower abdominal problems (intestinal/lower
abdominal pain/cramping, flatulence, urge to defecate, side aches/stitch,
loose stool, diarrhea); and 3) systemic problems (dizziness, headache,
muscle cramps, urge to urinate).25 Symptoms are scored on a 10-point
scale (0¼ no problems at all and 9¼ the worst it has ever been). A
score >4 was considered “serious”.26 Questionnaires were administered
pre-, post-, 3 h post-, and at the time of the post-exercise fecal sample
(~24 h post-exercise).
Utilizing the above mentioned GI symptom index, a scale was
developed to determine upper, lower, and systemic GI symptoms during
exercise. Participants were asked every 15min “Are you currently
experiencing GI symptoms?” If the participant answered “yes”, they were
asked to verbalize the symptom and rank the severity on a 10-point scale
(0¼ no problems at all and 9¼ the worst it has ever been).
Hydration measures
Participants were required to be euhydrated before data collection.
Hydration status was determined using a urine sample at pre-, post-, and
3 h post-exercise. A handheld clinical refractometer (model REF 312,
Atago Company Ltd., Tokyo, Japan) measured urine specific gravity
(Usg); euhydration was defined as 1.020.27 To maintain hydration
during exercise, participants were required to drink a minimum of
3.5 ml kg1 of water every 15min; participants could drink more fluid if
they desired. Total fluid volume consumed during exercise was recorded.
Participants consumed water ad libitum during the 3 h rest after exercise
and fluid volume was recorded.
Diet and activity logs
To control potential effects on GI distress and performance, partici-
pants self-reported diet and physical activity for 3 days before and 1 day
after data collection using the online nutrition software FoodProdigy™
(ESHA Research, Salem, OR). Participants were asked to mimic dietary
and physical activity habits during the 24 h before each data collection
session. Additionally, participants were instructed to refrain from eating
red meat for 3 days before and 1 day after due to the potential to skew
FOB tests.
Pre-data collection
Participants received email instructions for completing the diet and
physical activity log 72 h before data collection. Participants were
instructed to refrain from intense, vigorous exercise 48 h before.28
Twenty-four hours before, participants received written directions for
taking 2 capsules (placebo or naproxen) and reminders for diet, hydra-
tion, and activity. To ensure food passed through the stomach before data
collection, participants were instructed to consume a small meal at least
2 h before arriving at the laboratory.
Data collection session
Upon arriving at the laboratory, participants were asked if they
ingested their 2 pills then instructed to take their third pill. Participants
provided a urine sample and voided their remaining urine into the toilet.
Baseline Usg was measured to ensure participants were euhydrated.
Participants received a HRmonitor and the cycling protocol began. Every
15min, a research assistant asked participants their RPE and GI symp-
toms. Heart rate and distance travelled during the final 10min was
recorded and participants were asked their RPE and GI symptoms.
Following a 5min cool down on the bike, participants completed a post-
GI symptom index and provided a urine sample. The larger study21required participants rest 3 h in a semi-reclined/seated position in an
ambient environment (23C, 56% RH). During the rest period partici-
pants consumed water ad libitum and received a non-sucrose snack
(crackers andwafers) based on body weight, which was the same for each
trial. Dependent variables were measured at the end of the rest period.Statistical analysis
IBM SPSS Statistics (version XV; IBM Corporation, Armonk, NY) was
used for all analyses. Descriptive statistics (mean and standard de-
viations) were calculated for demographics and dependent variables.
Using G*Power (version 3.1.9.2, Heinrich Heine University, Dusseldorf,
Germany),29 post-hoc power calculations with means and variances for
maximum HR and distance indicated a statistical power> 0.9. Signifi-
cance level was set at p< 0.05 for all analyses.
Dietary (e.g., calories, protein), distance, maximumHR, and Usg were
assessed using one-way ANOVA. A 4 (condition) x 8 (time) repeated
measures ANOVA determined RPE differences. Because RPE violated
sphericity, Greenhouse-Geisser corrections were used. Post-hoc analysis
was conducted for significant effects with Bonferroni corrections.
Freidman's ANOVA identified differences in GI symptoms between and
within conditions. Questions were sectioned into upper, lower, and sys-
temic symptoms to reduce multiplicity; responses were averaged and
analysed. Post-hoc analysis was conducted using pairwise comparisons
with Bonferroni corrections. Frequency for each GI symptom was
calculated to determine percent incidence. Chi-square analysis deter-
mined differences in percent of symptoms scored >4 (considered
“serious”) between conditions and across time. To control for other fac-
tors that may influence GI symptoms, Spearman's rho correlations were
run for maximum HR, maximum RPE, and distance. Specific Tc results
are not presented as part of this study and hydration results are published
elsewhere30; spearman's rho correlations were conducted for GI symp-
toms to Tc at the end of the 10min maximum effort and fluid volume
during exercise to determine potential effects.
Results
Participants began experimental trials euhydrated (mean
Usg¼ 1.012 0.005) and maintained euhydration throughout exercise
(1.011 0.008) and recovery (1.007 0.006). Diet analysis indicated no
significant differences between conditions for calorie, fat, protein, car-
bohydrate, or sodium intake. No significant differences in exercise (cal-
ories burned) 24 h before data collection existed, with all participants
maintaining sedentary to low activity. There was no significant differ-
ence for mean Tc at 90min (overall¼ 38.2 0.3C) or fluid volume
(overall¼ 1.5 0.7 L) during exercise between experimental conditions.Performance
Table 1 shows distance, RPE, and maximum HR during 10min
maximum effort for each condition. There was an overall significant main
effect (F2.8,110.3¼ 163.3, p< 0.001) for increased RPE over time, but no
significant differences between conditions. Distance and maximum HR
were not significantly different between conditions (Table 2).
Table 2
Mean and maximum gastrointestinal symptom scores for experimental conditions.
Symptoms Control Heat Npx NpxHeat
Incidence Max (M SD) Incidence Max (M SD) Incidence Max (M SD) Incidence Max (M SD)
Upper
Reflux/Heartburn 0% – 2.3% 6 (0.1 0.9) 0% – 0% –
Belching 4.5% 1 (0.1 0.4) 4.6% 6 (0.2 0.9) 0% – 4.5% 4 (0.1 0.6)
Bloating 6.8% 5 (0.4 1.2) 6.8% 6 (0.5 1.3) 11.4% 2 (0.2 0.4) 4.5% 2 (0.2 0.8)
Stomach pain 11.4% 2 (0.3 0.6) 9.1% 6 (0.4 1.3) 6.8% 2 (0.2 0.5) 6.8% 2 (0.3 1.1)
Vomiting 0% – 4.5% 2 (0.2 1.1) 0% – 4.5% 2 (0.2 1.1)
Nausea 9.1% 3 (0.2 0.5) 13.7% 6 (0.5 1.4) 2.3% 1 (0.0 0.2) 11.4% 3 (0.3 1.2)
Lower
Intestinal cramps 13.6% 2 (0.3 0.7) 6.8% 8 (0.5 1.6) 2.3% 1 (0.0 0.2) 4.5% 2 (0.2 1.2)
Flatulence 13.6% 3 (0.3 0.8) 11.4% 4 (0.3 0.9) 6.8% 2 (0.1 0.5) 6.8% 5 (0.3 1.0)
Urge to defecate 11.4% 5 (0.4 1.0) 9.1% 6 (0.5 1.5) 6.8% 4 (0.2 0.7) 6.8% 7 (0.3 1.4)
Abdominal pain 0% – 4.5% 2 (0.1 0.5) 0% – 0% –
Loose stool/Diarrhea 0% – 4.5% 4 (0.4 1.5) 0% – 4.6% 7 (0.4 1.7)
Systemic
Dizziness 9.1% 3 (0.1 0.5) 13.6% 3 (0.2 0.7) 2.3% 2 (0.1 0.3) 6.8% 3 (0.2 0.6)
Headache 36.4% 5 (0.6 1.0) 18.2% 5 (0.3 0.9) 9.1% 2 (0.1 0.4) 18.2% 3 (0.2 0.6)
Muscle cramps 2.3% 3 (0.1 0.4) 2.3% 6 (0.1 0.9) 2.3% 1 (0.0 0.2) 0% –
Urge to urinate 22.7% 8 (0.8 1.9) 31.8% 8 (0.9 1.7) 27.2% 7 (0.9 1.7) 13.7% 5 (0.5 1.2)
Percent incidence based on aggregate scores for each symptom reported at pre-, post-, 3 h post-, and 24 h post-exercise. Symptoms scored on a 0–9 scale.
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Fecal occult blood
There were no positive FOB tests pre-exercise. One positive FOB test
indicated GI bleeding post-exercise in the Npx condition. However, this
test was likely a false positive because it occurred in a menstruating
participant.
GI symptoms pre-post exercise
Percent incidence and maximum and mean scores for individual GI
symptoms were aggregated across time (pre-to 24 h post-exercise) and
presented in Table 2. Compared to other time points, at 24 h post-
exercise Heat experienced significantly more serious scores for reflux/
heartburn, belching, bloating, stomach pain, nausea, intestinal cramps,
flatulence, urge to defecate, loose stool/diarrhea, headache, and muscle
cramps (χ2(3)¼ 8.5, p¼ 0.037).
Significant main effects occurred for aggregated upper (χ2(3)¼ 7.8,
p¼ 0.049), lower (χ2(3)¼ 10.9, p¼ 0.012), and systemic (χ2(3)¼ 8.4,
p¼ 0.038) GI symptoms at 3 h post-exercise between conditions. Post-
hoc analysis indicated Control had higher mean scores, but this was
not statistically significant. There were no other differences between
conditions at any time point. Within conditions, there were significantTable 3
Mean and maximum gastrointestinal symptom scores for experimental conditions du
Symptoms Control Heat
Incidence Max (M SD) Incidence Max
Upper
Reflux/Heartburn 0% – 0% –
Belching 0% – 0% –
Bloating 0% – 4.5% 4 (0.1
Stomach pain 0% – 4.5% 4 (0.1
Vomiting 0% – 1.1% 5 (0.1
Nausea 4.5% 8 (0.2 0.9) 2.3% 7 (0.1
Lower
Intestinal cramps 13.6% 3 (0.3 0.9) 4.5% 4 (0.1
Flatulence 2.3% 1 (0.0 0.1) 0% –
Urge to defecate 0% – 1.1% 4 (0.0
Abdominal pain 0% – 0% –
Loose stool/Diarrhea 0% – 0% –
Systemic
Dizziness 3.4% 4 (0.1 0.5) 1.1% 5 (0.1
Headache 9.1% 4 (0.2 0.9) 1.1% 4 (0.0
Muscle cramps 0% – 0% –
Urge to urinate 20.4% 8 (0.8 1.9) 10.2% 7 (0.4
22main effects across time for upper symptoms in Control (χ2(3)¼ 9.0,
p¼ 0.029) and systemic symptoms in Npx (χ2(3)¼ 7.9, p¼ 0.048); post-
hoc analysis indicated post-exercise scores were higher than any other
time, but these were not statistically significant. No differences occurred
within Heat or NpxHeat.
GI symptoms during exercise
Percent incidence and maximum and mean scores for individual GI
symptoms during exercise are presented in Table 3. NpxHeat reported
less serious scores for urge to urinate compared to other conditions
(χ2(3)¼ 8.7, p¼ 0.033). There were no other significant differences for
individual symptoms or aggregated upper, lower or systemic symptom
scores between conditions.Correlations
We identified no significant correlations for GI symptoms to fluid
volume, Tc, maximum RPE, or maximum HR within trials. During Heat,
we found a significant positive correlation between lower and upper
(rs¼ 0.9, p¼ 0.001) and lower and systemic (rs¼ 0.7, p¼ 0.03) GI
symptoms. When examining correlations between non-GI measures, we
found a significant positive correlation between maximum RPE and HRring exercise.
Npx NpxHeat
(M SD) Incidence Max (M SD) Incidence Max (M SD)
1.1% 2 (0.0 0.2) 0% –
0% – 0% –
 0.5) 3.4% 3 (0.1 0.3) 1.1% 2 (0.0 0.2)
 0.6) 5.7% 2 (0.1 0.4) 0% –
 0.5) 0% – 1.1% 7 (0.1 0.7)
 0.9) 1.1% 8 (0.1 0.8) 1.1% 7 (0.1 0.7)
 0.6) 0% – 9.1% 3 (0.1 0.4)
0% – 0% –
 0.4) 2.3% 4 (0.1 0.4) 2.3% 4 (0.1 0.6)
0% – 0% –
0% – 0% –
 0.5) 0% – 0% –
 0.4) 0% – 0% –
0% – 0% –
 1.5) 26.1% 8 (0.9 1.9) 5.6% 5 (0.1 0.7)
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(rs¼ 0.6, p¼ 0.043), but not for NpxHeat. Distance travelled correlated
significantly to maximum RPE during Npx (rs¼ 0.6, p¼ 0.044) and to Tc
during NpxHeat (rs¼ 0.7, p¼ 0.028).
Discussion
We sought to determine whether a 24 h naproxen dose would nega-
tively affect performance and induce GI symptoms during exercise in the
heat. We chose this dose to identify acute effects from the over-the-
counter strength medication using the recommended 1 pill every 8 h.
Our results indicate, compared to placebo, an acute naproxen dose did
not negatively impact RPE, distance, or maximum HR and did not
significantly increase GI symptoms.
Performance
Contrary to our hypothesis, naproxen did not significantly decrease
performance in either an ambient or thermal environment. Using a low
naproxen dose is a potential explanation for the lack of statistical sig-
nificance. Less COX-2 selectivity and shorter half-lives mean higher
aspirin and ibuprofen doses are recommended to elicit anti-inflammatory
and analgesic effects. Consequently, and compared to our naproxen dose,
higher aspirin and ibuprofen doses are seen in the literature.9–12
Increasing the naproxen dose (i.e., prescription strength) and extending
time used (i.e., more than 24 h) could elicit different, more significant
performance or GI responses. This concept is supported when examining
acute versus chronic aspirin use, with acute only affecting RPE and
chronic aspirin use negatively affecting RPE, lactate, hematocrit, and
fatigue.9
Participants in the present study were euhydrated throughout exer-
cise; therefore, increased HR was not dehydration induced but was
associated with experimental conditions. The high correlation between
maximum HR and maximum RPE in all conditions (except for NpxHeat)
suggests participants were able to accurately assess their RPE and were
exhibitingmaximum effort at 90min. Though not statistically significant,
NpxHeat averaged fewer miles with higher HR and RPE compared to
Heat. Slightly different results occurred among ambient conditions.
Again, these were not statistically significant, but naproxen resulted in
the greatest distance covered with no change in RPE and slightly higher
HR. Keeping in mind NSAID effects on the cardiovascular system (vaso-
constriction and increased blood pressure) and the cardiovascular sys-
tem's response to intense exercise under thermal stress (increased HR to
maintain cardiac output),31 combining naproxen and heat could increase
cardiovascular strain and maximum RPE, resulting in less distance. The
potential environment influence when taking naproxen and exercising
needs to be further elucidated.
Gastrointestinal distress
The etiology for GI distress is not well understood but is suggested to
be attributed to mechanical vibrations,32 GI ischemia-reperfusion,33 and
inflammatory responses.33,34 Symptoms experienced in our study (i.e.,
nausea, diarrhea, vomiting) were similar to runners.35 However,
considering the prevalence of GI bleeding during running,18 we were
surprised to find a lack of positive FOB tests, particularly with the
NpxHeat. We likely attenuated the incidence for GI bleeding by using a
less impactful exercise (cycling) and a shorter, moderate-intense exercise
bout.
Naproxen did not significantly increase GI distress compared to pla-
cebo. One interesting finding is that naproxen prevented dizziness and
headache during exercise in both heat and ambient trials, but this effect
was not observed before or after exercise. Though they were not signif-
icantly different, during Npx participants reported reflux/heartburn,
bloating, and stomach pain, which were not reported during Control, and
vomiting was only reported during heat trials. The only significant23difference for individual GI symptoms between conditions occurred for
urge to urinate, but in general was lower for both heat trails. Urination
was likely mitigated by increased fluid needs in the hot environment due
to sweating. Interestingly, higher incidence and serious scores were re-
ported 24 h post-for Heat compared to ambient trials, and NpxHeat
approached significance. These data suggest lingering effects from ex-
ercise in a hot environment, which was to some extent alleviated by
naproxen. We did not assess physiological measures 24 h post-, but ex-
ercise and thermal stress induce inflammatory responses24 that can last
hours to days after.36 Increased inflammation could explain higher GI
symptoms 24 h post- and is an important consideration for individuals
exercising on consecutive days, particularly in the heat.
In the present study, GI distress did not correlate with fluid volume
consumed, Tc, maximum HR, or maximum RPE. Symptoms were most
likely influenced by exercise, environment, and/or the presence of other
GI symptoms. Performance variables seemed to be influenced more by
one another, particularly between RPE and HR. Menstrual phase was not
initially controlled for, but post-hoc analysis showed GI symptoms were
not different for trials conducted during menstruation.
Limitations and future research
We assume participants were honest when answering the GI symptom
indexes and that participants consumed the first 2 pills as instructed. We
did not measure V_O2max or power output during exercise. Therefore, we
must use HR and RPE to base our assumption that participants gave the
same maximum effort each trial. Using a constant HR rather than V_O2max
resulted in lower exercise intensity during heat trials because HR natu-
rally increased in response to thermal strain. This forced participants to
cycle at lower intensity to maintain target HR during the steady state.
Less intensity may explain the lower percentage of incidence and serious
GI symptoms in the heat. Frequency and severity for urge to urinate
during and post-exercise were likely skewed by forcing participants to
drink to maintain euhydration, making it difficult to determine actual
naproxen effects. This limitation would be mitigated if participants drank
the same fluid volume during each trial. Another potential limitation was
using guaiac-based FOB, which has high specificity but low sensitivity,
meaning it may not have been able to detect blood in the fecal samples,
resulting in false negatives.
Future research should examine different NSAID dosages (e.g., pre-
scription strength) and length of use (e.g., 3 days, 7 days). It is pertinent
to examine effects in hypohydrated individuals, which would increase
cardiovascular strain, GI distress, and perceived exertion in ambient and
hot conditions. Using a carbohydrate electrolyte beverage for rehydra-
tion would introduce potential GI distress. Research is needed on
different exercise modes, intensities, and durations and to identify po-
tential differences between males and females.
Conclusion
Similar to previous studies using aspirin9–11 and ibuprofen,12 taking a
24 h over-the-counter naproxen dose did not improve or negatively affect
performance. Our results are applicable to healthy, euhydrated, moder-
ately trained individuals exercising at a given HR (e.g., as a way to
maintain pace) prior to a maximum effort. An acute naproxen dose also
did not cause GI bleeding or significantly increase upper, lower, or sys-
temic GI symptoms during and after exercise. Bearing in mind NSAIDs’
well-established effects on the cardiovascular and GI systems,14,15,19,21,37
as well as our trend for higher HR with lower distance, consideration
should be made for individuals taking naproxen before exercise in the
heat, particularly if these individuals have predisposing factors that could
compromise physiological function.
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